Single-point and kinetics of peripheral residual disease by mass spectrometry to predict outcome in patients with high-risk smoldering multiple myeloma included in the GEM-CESAR trial.
Puig N, Agulló C, Contreras T, Pérez JJ, Aires I, Calasanz MJ, García-Sanz R, Castro S, Martínez-López J, Rodríguez-Otero P, González-Calle V, González MS, Oriol A, Gutiérrez NC, Ríos-Tamayo R, Rosiñol L, Álvarez MÁ, Bargay J, González-Rodríguez AP, Alegre A, Escalante F, Iñigo MB, De la Rubia J, Teruel AI, De Arriba F, Palomera L, Hernández MT, López-Jiménez J, Reinoso M, García-Mateo A, Ocio EM, Bladé J, Lahuerta JJ, Cedena MT, Paiva B, Miguel JFS, Mateos MV.
Puig N, et al. Among authors: reinoso m.
Haematologica. 2024 Dec 1;109(12):4056-4066. doi: 10.3324/haematol.2024.285742.
Haematologica. 2024.
PMID: 38988266
Free PMC article.
Clinical Trial.